Pfizer Worldwide Research and Development, Sandwich, Kent, UK.
Mol Divers. 2013 May;17(2):319-35. doi: 10.1007/s11030-013-9438-x. Epub 2013 Apr 5.
The screening files of many large companies, including Pfizer, have grown considerably due to internal chemistry efforts, company mergers and acquisitions, external contracted synthesis, or compound purchase schemes. In order to screen the targets of interest in a cost-effective fashion, we devised an easy-to-assemble, plate-based diversity subset (PBDS) that represents almost the entire computed chemical space of the screening file whilst comprising only a fraction of the plates in the collection. In order to create this file, we developed new design principles for the quality assessment of screening plates: the Rule of 40 (Ro40) and a plate selection process that insured excellent coverage of both library chemistry and legacy chemistry space. This paper describes the rationale, design, construction, and performance of the PBDS, that has evolved into the standard paradigm for singleton (one compound per well) high-throughput screening in Pfizer since its introduction in 2006.
由于内部化学研究、公司合并收购、外部合同合成或化合物购买计划,许多大公司的筛选文件都有了相当大的增长。为了以具有成本效益的方式筛选出感兴趣的目标,我们设计了一种易于组装的、基于平板的多样性子集(PBDS),它代表了筛选文件中几乎整个计算化学空间,而只包含该集合中平板的一小部分。为了创建这个文件,我们为筛选板的质量评估开发了新的设计原则:40 规则(Ro40)和一个平板选择过程,该过程确保了库化学和遗留化学空间的出色覆盖。本文描述了 PBDS 的原理、设计、构建和性能,自 2006 年引入以来,它已成为辉瑞公司单化合物(每个孔一个化合物)高通量筛选的标准范例。